Norwegian biotechnology company Hofseth Biocare (HBC) reported that the financial year for 2019 closed out with more losses in the last quarter, but says a recently signed joint venture deal with land-based salmon farmer Atlantic Sapphire is developing positively.
The company's earnings before interest, taxes, depreciation, and amortization were at negative NOK 15 million (€1.5 million/$1.6 million) for the fourth quarter of 2019, a 15 percent increase in losss from the same period last year, while operating loss was at NOK 23 million (€2.3
